Literature DB >> 6357070

Evaluation of an automated fluorescence polarization immunoassay for vancomycin.

B H Filburn, V H Shull, Y M Tempera, J D Dick.   

Abstract

An automated fluorescence polarization immunoassay for the determination of vancomycin levels in serum was evaluated. The vancomycin assay is a homogeneous competitive inhibition immunoassay based on changes in fluorescence polarization that occur with antibody binding. This assay was compared with a liquid chromatographic assay and an agar well diffusion bioassay method by using clinical serum specimens and controls. Linear regression analysis of the data obtained on clinical specimens by the three methods resulted in correlation coefficients of 0.97 for the fluorescence polarization immunoassay versus the liquid chromatographic assay (n = 60), 0.90 for the fluorescence polarization immunoassay versus the bioassay (n = 57), and 0.90 for the liquid chromatographic assay versus the bioassay (n = 57). Repetitive analysis of control sera containing 7, 35, and 75 micrograms of vancomycin per ml by the fluorescence polarization immunoassay yielded coefficients of variation of 3.0, 1.7, and 2.3, respectively. No interference was demonstrated in spiked hemolytic, lipemic, or icteric sera, and the assay was free of matrix effects. The automated fluorescence polarization immunoassay system offers a rapid, efficient, and accurate method for monitoring vancomycin serum levels for both toxicity and efficacy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6357070      PMCID: PMC185140          DOI: 10.1128/AAC.24.2.216

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Treatment of staphylococcal septicemia with vancomycin: report of thirty-three cases.

Authors:  W M KIRBY; D M PERRY; A W BAUER
Journal:  N Engl J Med       Date:  1960-01-14       Impact factor: 91.245

2.  Simple method for elimination of aminoglycosides from serum to permit bioassay of other antimicrobial agents.

Authors:  P Stevens; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

3.  Vancomycin.

Authors:  J E Geraci
Journal:  Mayo Clin Proc       Date:  1977-10       Impact factor: 7.616

4.  Sensitive bioassay for vancomycin.

Authors:  C A Walker; B Kopp
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

5.  Susceptibility of "methicillin"-resistant Staphylococcus aureus to 12 antimicrobial agents.

Authors:  P D Hoeprich; E J Benner; F H Kayser
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

6.  Fluorescence polarization immunoassay for the determination of therapeutic drug levels in human plasma.

Authors:  M E Jolley
Journal:  J Anal Toxicol       Date:  1981 Sep-Oct       Impact factor: 3.367

7.  Fluorescence polarization immunoassay. iii. an automated system for therapeutic drug determination.

Authors:  M E Jolley; S D Stroupe; K S Schwenzer; C J Wang; M Lu-Steffes; H D Hill; S R Popelka; J T Holen; D M Kelso
Journal:  Clin Chem       Date:  1981-09       Impact factor: 8.327

8.  Sensitive radioimmunoassay for vancomycin.

Authors:  K L Fong; D H Ho; L Bogerd; T Pan; N S Brown; L Gentry; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

9.  Vancomycin for staphylococcal shunt site infections in patients on regular haemodialysis.

Authors:  S Eykyn; I Phillips; J Evans
Journal:  Br Med J       Date:  1970-07-11

10.  Synergism of vancomycin-gentamicin and vancomycin-streptomycin against enterococci.

Authors:  C Watanakunakorn; C Bakie
Journal:  Antimicrob Agents Chemother       Date:  1973-08       Impact factor: 5.191

View more
  9 in total

1.  Methods for reducing bacterial contamination in the BacT/Alert mycobacterial culture detection system.

Authors:  Kim Dionne; Amy Sweeney; Annie Hedgepeth; Karen Carroll; Nicole Parrish
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

2.  Protein binding of vancomycin in a patient with immunoglobulin A myeloma.

Authors:  T G Cantú; J D Dick; D E Elliott; R L Humphrey; D M Kornhauser
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

3.  Vancomycin Serum Concentration Monitoring : The Middle Ground is Best.

Authors:  F Marra; B Cairns; P Jewesson
Journal:  Clin Drug Investig       Date:  1996-08       Impact factor: 2.859

4.  Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery.

Authors:  Keso Skhirtladze; Doris Hutschala; Tatjana Fleck; Florian Thalhammer; Marek Ehrlich; Thomas Vukovich; Markus Müller; Edda M Tschernko
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

5.  Laboratory evaluation of five assay methods for vancomycin: bioassay, high-pressure liquid chromatography, fluorescence polarization immunoassay, radioimmunoassay, and fluorescence immunoassay.

Authors:  M A Pfaller; D J Krogstad; G G Granich; P R Murray
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

6.  Comparison of fluorescence polarization immunoassay and bioassay of vancomycin.

Authors:  D J Pohlod; L D Saravolatz; M M Somerville
Journal:  J Clin Microbiol       Date:  1984-08       Impact factor: 5.948

Review 7.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

8.  Development and validation of an HPLC method for the determination of vancomycin in human plasma and its comparison with an immunoassay (PETINIA).

Authors:  Muhammad Usman; Georg Hempel
Journal:  Springerplus       Date:  2016-02-18

9.  Stability-indicating spectrofluorimetric method with enhanced sensitivity for determination of vancomycin hydrochloride in pharmaceuticals and spiked human plasma: Application to degradation kinetics.

Authors:  Mohie Khaled Sharaf El-Din; Fawzia Ibrahim; Asmaa Kamal El-Deen; Kuniyoshi Shimizu
Journal:  J Food Drug Anal       Date:  2017-07-08       Impact factor: 6.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.